|
|
| Research article summary (published 30 Oct 2009): |
A novel model of bone-metastatic prostate cancer in immunocompetent mice.
Full Abstract
BACKGROUND: Bone metastasis is a frequent and catastrophic consequence of prostate cancer for which only palliative treatment is available. Animal models of bone metastatic prostate cancer are necessary for understanding disease mechanisms but few models exist. METHODS: We have used the murine prostate carcinoma cell line RM1 to generate a bone metastatic model of prostate cancer. Repeated intracardiac injection of RM1 cells followed by isolation of cells from bone tumors has yielded a cell line with strong bone-metastatic potential, RM1 bone metastatic (BM). RESULTS: This cell line metastasizes to multiple bony sites in over 95% of injected C57BL/6 mice and is far less tropic to soft tissues. Bone tumors produced by the RM1(BM) cell line show no preference for particular skeletal sites as most bones are affected. Histology, and micro-computed tomography show that RM1(BM) cells form osteolytic tumors, but with evidence of osteoblastic changes. In vitro the RM1 cells express E-cadherin but not vimentin, do not form colonies in soft agar, are non-invasive but are more motile than the parent cell line. CONCLUSIONS: This model provides a novel means for identifying cellular and molecular mechanisms that contribute to bone metastasis and allow for preclinical testing of therapies to prevent and treat tumor metastasis to bone. Finally as the syngeneic tumor cells are injected into immunocompetent mice, this model will provide a means to study interactions between the immune system, tumors and bone, and therapies that target such interactions.
Author information
Author/s: Power, Carl A (CA); Pwint, Hnin (H); Chan, Jeffrey (J); Cho, Jae (J); Yu, Yan (Y); Walsh, William (W); Russell, Pamela J (PJ);
Affiliation: Oncology Research Centre, Prince of Wales Hospital, Randwick, NSW, Australia. c.power(-atsign-)unsw.edu.au
Grants: CA 03-013 (Agency:NCI NIH HHS)
Journal and publication information
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal: The Prostate (Prostate), published in United States. (Language: eng)
Reference: 2009-Nov; vol 69 (issue 15) : pp 1613-23
Dates: Created 2009/09/28; Completed 2009/10/15;
PMID: 19585491, status: MEDLINE (last retrieval date: 10/15/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
30 Dec 1991 - Survival markers related to bone metastases in prostate cancer.
30 Oct 2006 - Serum interleukin-8 is elevated in men with prostate cancer and bone metastases.
29 Sep 2004 - Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
30 Jan 1997 - Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?
30 Dec 1991 - Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
30 Dec 1982 - [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients]
30 Jul 1991 - [Comparative study between acid phosphatases and bone gammagraphy in cancer of the prostate]
30 Dec 1984 - Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
29 Apr 2008 - Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer.
27 Feb 2007
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.